Stabilization of proteins encapsulated in injectable poly (lactide-co- glycolide)

Nature Biotechnology

Volumn 18, Issue 1, 2000, Pages 52-57

  Zhu, Gaozhong ^a,b   Mallery, Susan R ^a   Schwendeman, Steven P ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BIOGEN   (United States)

Author keywords

Aggregation; Bovine serum albumin; Poly(DL lactide co glycolide; Protein delivery; Stabilization

Indexed keywords

ANGIOGENIC FACTOR; ANTACID AGENT; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; M PROTEIN; MAGNESIUM HYDROXIDE; POLYGLACTIN; POLYMER;

ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION;

3T3 CELLS; ANIMALS; ANTACIDS; BONE MORPHOGENETIC PROTEINS; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DISULFIDES; DRUG STABILITY; FIBROBLAST GROWTH FACTOR 2; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; ISOELECTRIC POINT; MICE; MICROSPHERES; MOLECULAR WEIGHT; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; POLYGLACTIN 910; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEINS; SERUM ALBUMIN; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; WATER;

BOVINAE;

EID: 0033986610     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/71916     Document Type: Article

References (45)

1. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800 (1976).
2. Struck, M.M. Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future. Bio/Technology 12, 674-677 (1994).
3. Talmadge, J.E. The pharmaceutics and delivery of therapeutic polypeptides and proteins. Adv. Drug Delivery. Rev. 10, 247-299 (1993).
4. Ogawa, Y., Okada, H., Heya, T. & Shimamota T. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmcol. 41, 439-444 (1989).
5. Okada, H., Doken, Y., Ogawa, Y. & Toguchi, H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm. Res. 11, 1143 (1994).
6. Dutta, A.S., Furr, B.J.A. & Hutchinson, F.G. Discovery and development of goserelin (Zoladex). Pharm. Med. 7, 9-28 (1993).
7. Schwendeman, S.P., Cardamone, M., Klibanov., A. & Langer, R. in Microparticulate systems for the delivery of proteins and vaccines (eds Cohen, S. & Bernstein, H.), 1-49 (Marcel Dekker, New York; 1996).
8. Schwendeman, S.P., Costantino, H.R., Gupta, R.K. & Langer, R. in Controlled drug delivery, (ed. Park, K.), 229-267 (American Chemical Society, Washington, D.C; 1997).
9. Johnson, O.L. et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2, 795-799 (1996).
10. Cleland, J.L. & Jones, A.J.S. Stable formulations of recombinant human growth hormone and inlerferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 13, 1464-1475 (1996).
11. Schwendeman, S.P., Tobio, M., Joworowicz, M., Alonso, M.J. & Langer, R. New strategies for the microencapsulation of tetanus vaccine. J. Microencapsulation 15, 299-318 (1998).
12. Putney, S.D. & Burke, P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16, 153-157 (1998).
13. Costantino, H.R., Langer, R. & Klibanov, A.M. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sci. 83, 1662-1669 (1994).
14. Herrlinger, M. Ph.D. In vitro polymerabbau und wirksttofffreigabe von poly-DL-laktidformlingen Thesis, Univ. Heidelberg, Germany (1994).
15. Shenderova, A., Burke, T. & Schwendeman, S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16, 241-248 (1999).
16. Brunner, A., Mäder, K. & Göpferich, A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm. Res. 16, 847-853 (1999).
17. Mader, K., Bittner, B., Li, Y., Wohlauf, W. & Kissel, T. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks. Pharm. Res. 15, 787-793 (1998).
18. Fu, K., Pack, D.W., Laverdiere, A., Son, S. & Langer, R. Visualization of pH in degrading polymer microspheres. Proceedings 25th International Symposium on Controlled Resealse of Bioactive Materials 25, 150-151 (1998).
19. Mader, K.,Gallez, B., Liu, K.J. & Swartz, H.M. Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy. Biomaterials 17, 457-461 (1996).
20. Peters, T. Jr. Serum albumin. Adv. Protein Chem. 37, 161-245 (1985).
21. Manning, M.C., Patella, L & Borchardt, RT. Stability of protein pharmaceuticals. Pharm. Res. 6, 903-917 (1989).
22. Heller, J. Development of poly(ortho esters): a historical overview. Biomaterials 11, 659-665 (1990).
23. Li, S.M., Garreau, H. & Vert, M. Structure-property relationships in the case of the degradation of massive poly(a-hydroxy acids) in aqueous media. Part 3. Influence of the morphology of poly(L-lactic acid). J. Mater. Sci. 1, 123-130 (1990).
24. Hutchinson, F.G. & Furr, B.J.A. Biodegradable polymer systems for the sustained release of polypeptides. J. Controlled Release13, 279-294 (1990).
25. Wang, Y.J. et al. in Formulation, characterization, and stability of protein drugs (eds Pearlman, R. & Wang, Y.J.) 141-180 (Plenum Press, New York; 1996).
26. Edelman, E.R., Nugent, M.A. & Karnovsky, M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. USA 90, 1513-1517 (1993).
27. Berscht, P.C., Nies, B., Liebendorfer, A. & Kreuter, J. Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics. Biomaterials 15, 593-600 (1994).
28. Fukunaga, K. et al. Aluminium beta-cyclodextrin sulphate a stabilizer and sustained-release carrier for basic fibroblast growth factor. J. Pharm. Pharmacol. 46, 168-171 (1994).
29. Edelman, E.R., Mathiowitz, E., Langer, R. & Klagsbrun, M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12, 619-626 (1991).
30. Davies, M.J. et al. In vitro assessment of the biological activity of basic fibroblast growth factor released from various polymers and biomatrices. Journal of Biomaterial Applications 12, 31-56 (1997).
31. Wang, E.A. et al. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. USA 87, 2220-2224 (1990).
32. Welch, R.D. et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J. Bone Miner. Res. 13, 1483-1490 (1998).
33. Mayer, M., Hollinger, J., Ron, E. & Wozney, J. Maxillary alveolar cleft repair in dogs using recombinant human bone morphogenetic protein-2 and a polymer carrier. Plast. Reconstr. Surg. 98, 247-259 (1996).
34. Kenley, R.A. et al. Biotechnology and bone graft substitutes Pharm. Res. 10, 1393-1401 (1993).
35. Gospodarowicz, D. & Cheng, J. Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128, 475-484 (1986).
36. Sommer, A. & Rifkin, D.B. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell. Physiol. 138, 215-220 (1989).
37. Sullivan, R. & Klagsbrun, M. Purification and assay of intact human basic fibroblast growth factor using heparin-sepharose chromatography. J. Tiss. Culture Methods 10, 125-132 (1986).
38. Crotts, G., Sah, H. & Park, T.G. Adsorption determines in-vitro protein release rate from biodegradable microspheres: quantitative analysis of surface area during degradation. J. Controlled Release. 47, 101-111 (1997).
39. Zhang, X., Wyss, U.P, Amsden, B. & Goosen, M.F.A. Controlled release of albumin from biodegradable poly(DL-lactide) cylinders. J. Controlled Release 25, 61-69 (1993).
40. Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, LH. & Langer, R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8, 713-720 (1991).
41. Schwendeman, S.P. et al. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl. Acad. Sci. USA 92, 11234-11238 (1995).
42. Liu, W.R., Langer, R. & Klibanov, A.M. Moisture-induced aggregation of lyophilized proteins in the solid state. Biotechnol. Bioeng. 37, 177-184 (1991).
43. Shenderova, A., Burke, T.G. & Schwendeman, S.P. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res. 14, 1406-1413 (1997).
44. Watanabe, H. et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 175, 229-235 (1991).
45. Gabra, N., Khiat, A. & Calabresi, P. Detection of elevated basic fibroblast growth factor during early hours of in vitro angiogenesis using a fast ELISA immunoassay. Biochem. Biophys. Res. Commun. 205, 1423-1430 (1994).